The Personalized Chinese Herb Formulas Over Hypertensive Bradyarrhythmia

NCT ID: NCT04505228

Last Updated: 2020-08-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-20

Study Completion Date

2020-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

72 patients who have been diagnosed with hypertensive bradyarrhythmia were selected and randomly divided into research group and control group. The research group received regular medication against hypertension and the personalized formulas based on syndrome differentiation, meanwhile the control group only received the regular medication. The five symptoms (palpitation, short of breath, angina, dizzy and lumbar debility) were graded and used for evaluation of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To test the effect of Chinese herb against the hypertensive heart disease, we designed this randomized controlled clinical trial. 72 patients who have been diagnosed with hypertensive bradyarrhythmia were selected and randomly divided into research group and control group. The five symptoms (palpitation, short of breath, angina, dizzy and lumbar debility) were graded. The research group received regular medication against hypertension and the personalized formulas based on syndrome differentiation, meanwhile the control group only received the regular medication. 2 weeks after treatment, all the symptoms were graded again.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertensive Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Research group

The patients receiving Atropine and the extra Chinese herb formulas treatment

Group Type EXPERIMENTAL

Safflower (Carthamus Tinctorius) IgG4 | Serum | Allergy

Intervention Type DRUG

The designed Chinese herb formulas

Atropine Sulfate

Intervention Type DRUG

The basic treatment for heart disease

Control group

The patients receiving the basic treatment of atropine

Group Type ACTIVE_COMPARATOR

Atropine Sulfate

Intervention Type DRUG

The basic treatment for heart disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Safflower (Carthamus Tinctorius) IgG4 | Serum | Allergy

The designed Chinese herb formulas

Intervention Type DRUG

Atropine Sulfate

The basic treatment for heart disease

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xuefuzhuyu

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\* Clinical diagnosis of hypertensive bradyarhhythmia

Exclusion Criteria

* With other elementary diseases
* With pregnant
* With receiving other treatment within past half year from the beginning of trial.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qingdao Fifth People's Hospital

UNKNOWN

Sponsor Role collaborator

Jun Xiao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jun Xiao

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The fifth Qingdao people's hospital

Qingdao, Shandong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

qdms17337nsh

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of Chinese Herbal Therapy for Asthma
NCT00712296 TERMINATED PHASE1/PHASE2